Fresenius Medical Care will purchase a 19% stake in Humacyte, which closed a $75m series C round in March 2018.
Humacyte, a US-based developer of tissue-based medical spinout from Duke University, yesterday signed a $150m deal with healthcare company Fresenius Medical Care.
Fresenius Medical Care will own a 19% stake in Humacyte once the transaction closes next month and will become the exclusive distributor of Humacyte’s bioengineered blood vessel, Humacyl, after the product has secured regulatory approval.
Founded in 2004, Humacyte is developing regenerative medicine and vascular surgery technology and has products at the preclinical and clinical stage. The company’s…
